Interview with Mike “Zappy” Zapolin

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

MindMed (Nasdaq: MNMD, NEO: MMED) today announced that their Flagship Program, Project Lucy, has been given the green light from the FDA. MindMed is set to start a phase 2b Clinical Trial treating Generalized Anxiety Disorder with MM-102.
In response, MindMed’s stock has SKYROCKETED! It is up 39% at the time of writing and it could go higher. The psychedelic stock has been battered over the last 8 months, so it is good to see positive news affecting the price.
MindMed is a company attempting to treat mental health conditions such as Anxiety and Depression with Psychedelic Therapies.
Can psychedelics relieve anxiety and treat mental health? MindMed wants to know!

#MNMDstock# MindMed #Psychedelics

Hey guys! Today, we’ll cover Part 2 of our discussion on MindMed’s (MMED / MNMD / MMQ) conference call.
In the previous episode, we talked about the progress MindMed has made up until this point, MindMed’s mission, talent Acquisition, and the progress of their clinical trials.

In today’s episode, we will take a more futuristic approach and examine the future plans discussed in MindMed’s Q1 conference call. We will cover topics such as:

A. Where is MindMed going?
B. What is MindMed 2.0?
C. What will MindMed in 3 years time look like as compared to now?

Over the next several years, we expect 4 transformations to occur.
1. MindMed’s transition to a tech company, from a pharmaceuticals company;
2. The shift from classic psychedelics like LSD to “next generation” patent protected substances;
3. Reorientation away from one size fits all medical solutions towards personalized medicine;
4. Finding Partnerships with major pharmaceutical companies.

Timestamps:
0:00 – Intro
2:16 – MindMed transitioning to a tech company
7:14 -Next-gen shift
12:11 – Personalized medicine
13:59 – Partnerships

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MNMD #MindMedstock

BREAKING NEWS: Advisor Share Psychedelic Medicines ETF, PSIL, is going live THIS WEEK!!!!

Investing in ETFs can be a good way for retail investors to cash in on the shroom boom. This actively managed ETF will be managed by professionals who will do research on which companies have scientific and financial advantages.

PSIL will be on the NYSE, and will most likely feature companies such as MindMed (MNMD), Compass Pathways (CMPS), atai Life Sciences (atai), Numinus (NUMI) and more.

It will be a pure play psychedelics medicines ETF, and will not include marijuana companies (YAY). This means companies working with LSD, MDMA, Psilocybin and more. Primarily it is focused on improving mental health, so tackling problems like depression, PTSD addiction and more

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#AdvisorShares #PSIL #ThePsychedelicInvestor

Numinus Acquiring Novamind in First Major Psychedelics Merger

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

Not only will this be your chance to meet me, but also the legendary Paul Stamets!

Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…

Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Back to Numinus

This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.

Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).

The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.

If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.

#Numinus #NovaMind #psychedelicStocks